Mr. Bertram is the Head of Corporate Development at Petra Pharma. He joined Sangart in December 2008. He brings over 15 years of strategic marketing and sales experience in both international and local markets.
Prior to Sangart he has held senior strategic marketing positions in a number of pharmaceutical and biopharmaceutical companies. These include Senior Director of International Marketing at Pharmion, European Marketing Director at Chiron Biopharmaceuticals, Global Commercial Development at Celltech, as well as several Sales & Marketing positions at Eli Lilly and Company.
He is an experienced leader across many functions and countries with a specific focus on development and implementation of strategic and operational plans from early disease strategy through development and launch to established brands.
My only other comment (concern) is why, when the company is gearing up for what appears to be a productive transformative year, the previous CCO bails? Seems to me they could've been a little more forthcoming with the reasons other than the boilerplate response that "he is pursuing other opportunities". At least tell us whether or not he left of his own accord or you pushed him out because he sucks...
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM